Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00621985 · ClinicalTrials.gov registry record · Phase 2

Dexamethasone Treatment of Congenital Adrenal Hyperplasia

A Phase 2 study of Adrenal Hyperplasia, Congenital, sponsored by Boston Children's Hospital.

Completed
Registry status
Phase 2
Development phase
5
Enrollment target
1
Study location

NCT00621985 is a Phase 2 study of Adrenal Hyperplasia, Congenital that has completed, run by Boston Children's Hospital. The registered enrollment target is 5 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00621985, a Phase 2 study of Adrenal Hyperplasia, Congenital, has completed, sponsored by Boston Children's Hospital.

COMPLETED
Registry status
Phase 2
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if dexamethasone given at night is a more effective treatment for congenital adrenal hyperplasia in young children than standard three times per day hydrocortisone. Our hypothesis is that nocturnal dexamethasone will lead to more efficient suppression of the hypothalamic-pituitary-adrenal axis. We performed a cross-over trial comparing hormonal control during two 24-hour hospitalizations, one on hydrocortisone and one on nocturnal dexamethasone.

Interventions

  • DRUG Hydrocortisone
  • DRUG dexamethasone

Study Locations (1)

Massachusetts

  • Children's Hospital Boston - Boston

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2008-04
Est. Completion 2009-06
Phase Phase 2

Sponsor

Boston Children's Hospital

462 total trials

What the Registry Record Tells You About NCT00621985

The ClinicalTrials.gov registry entry for NCT00621985 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Adrenal Hyperplasia, Congenital appearing as the primary indexed condition, and to 2 interventions - of which Hydrocortisone is the first listed.

NCT00621985 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00621985 about?

NCT00621985 is a clinical study titled "Dexamethasone Treatment of Congenital Adrenal Hyperplasia". The purpose of this study is to determine if dexamethasone given at night is a more effective treatment for congenital adrenal hyperplasia in young children than standard three times per day hydrocortisone. Our hypothesis is that nocturnal dexamethasone will lead to more efficient suppression of the...

What is the current status of trial NCT00621985?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2008-04. Estimated completion is 2009-06.

What conditions does trial NCT00621985 study?

This clinical trial studies the following conditions: Adrenal Hyperplasia, Congenital.

What interventions are being tested in trial NCT00621985?

The interventions under investigation include: Hydrocortisone (DRUG), dexamethasone (DRUG).

Who is sponsoring clinical trial NCT00621985?

This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00621985 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adrenal Hyperplasia, Congenital

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.